Literature DB >> 19269865

Runx1 promotes B-cell survival and lymphoma development.

Karen Blyth1, Nicholas Slater, Linda Hanlon, Margaret Bell, Nancy Mackay, Monica Stewart, James C Neil, Ewan R Cameron.   

Abstract

Runx1 is essential for the homeostatic control of normal hematopoiesis and is required for lymphoid development. Translocations or point mutations that result in RUNX1 loss or disrupted function predispose to leukemia but data derived from model systems suggests that Runx genes can also be pro-oncogenic. Here we investigate the effects of enforced Runx1 expression in lymphoid lineages both in vivo and in vitro and show that transgene expression enhanced cell survival in the thymus and bone marrow but strongly inhibited the expansion of hematopoietic and B cell progenitors in vitro. Despite this, modestly enhanced levels of Runx1 accelerated Myc-induced lymphomagenesis in both the B cell and T cell lineages. Together these data provide formal proof that wild type Runx1 can promote oncogenesis in lymphoid tissues and that, in addition to loss of function, gain of function may have an aetiological role in leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269865     DOI: 10.1016/j.bcmd.2009.01.013

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  23 in total

1.  Over-expression of Runx1 transcription factor impairs the development of thymocytes from the double-negative to double-positive stages.

Authors:  Won F Wong; Megumi Nakazato; Toshio Watanabe; Kazuyoshi Kohu; Takehiro Ogata; Naomi Yoshida; Yusuke Sotomaru; Mamoru Ito; Kimi Araki; Janice Telfer; Manabu Fukumoto; Daisuke Suzuki; Takehito Sato; Katsuto Hozumi; Sonoko Habu; Masanobu Satake
Journal:  Immunology       Date:  2010-01-19       Impact factor: 7.397

2.  Quantifying deleterious effects of regulatory variants.

Authors:  Shan Li; Roberto Vera Alvarez; Roded Sharan; David Landsman; Ivan Ovcharenko
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

3.  Compound haploinsufficiencies of Ebf1 and Runx1 genes impede B cell lineage progression.

Authors:  Kara Lukin; Scott Fields; Desiree Lopez; Marie Cherrier; Kristina Ternyak; Julita Ramírez; Ann J Feeney; James Hagman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  RUNX transcription factors: association with pediatric asthma and modulated by maternal smoking.

Authors:  Kathleen J Haley; Jessica Lasky-Su; Sara E Manoli; Lacey A Smith; Aliakbar Shahsafaei; Scott T Weiss; Kelan Tantisira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-29       Impact factor: 5.464

5.  A germline point mutation in Runx1 uncouples its role in definitive hematopoiesis from differentiation.

Authors:  Christopher R Dowdy; Dana Frederick; Sayyed K Zaidi; Jennifer L Colby; Jane B Lian; Andre J van Wijnen; Rachel M Gerstein; Janet L Stein; Gary S Stein
Journal:  Exp Hematol       Date:  2013-06-30       Impact factor: 3.084

6.  Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.

Authors:  Nyam-Osor Chimge; Sara Ahmed-Alnassar; Baruch Frenkel
Journal:  Cell Cycle       Date:  2017-01-05       Impact factor: 4.534

7.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

Review 8.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.

Authors:  Gareth Brady; Hannah J Whiteman; Lindsay C Spender; Paul J Farrell
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

10.  Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity.

Authors:  Shabnam H Thathia; Stuart Ferguson; Hannah E Gautrey; Sanne D van Otterdijk; Michela Hili; Vikki Rand; Anthony V Moorman; Stefan Meyer; Robert Brown; Gordon Strathdee
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.